Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-Plus

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 7, 2005, Pages 765-770

  Ollé Goig, Jaime E ^a,b,c,e   Sandy, R ^d  

^a St Francis Hospital   (Uganda)

^b Catalan Association for the Control of Tuberculosis in the Third World (ACTMON)   (Spain)

^c German Leprosy Relief Association   (Bolivia)

^d Mycobacterial Laboratory   (Bolivia)

^e NONE   (Spain)

Author keywords

Bolivia; DOTS Plus; Multidrug resistance; Tuberculosis

Indexed keywords

CYCLOSERINE; ISONIAZID; KANAMYCIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; THIOACETAZONE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HEALTH PROGRAM; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; OUTPATIENT CARE; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 23744477142     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Pan American Health Organization. Regional Evaluation Meeting of National Tuberculosis Control Programs. México, 11-14 September, 2000. PAHO/HCP/HCT176/00. Washington, DC: PAHO, 2000.
2. World Health Organization. Global Tuberculosis Control. WHO Report 2001. Geneva, Switzerland: WHO, 2001.
3. Organización Panamericana de Salud. El control de la tuberculosis en las Américas: perfil de los países, 2000. OPS/HCP/ HCT/161/00. Washington, DC: OPS, 2000.
4. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world. WHO/TB/97.229. Geneva, Switzerland: WHO, 1997.
5. Espinal M, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
6. Lockman S, Kruuner A, Binkin N J, et al. Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis. Clin Infect Dis 2001; 32: 373-380.
7. Kritski A L, Rodrigues de Jesus L S, Andrade M K, et al. Retreatment of tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997; 111: 1162-1167.
8. Programa Nacional de Vigilancia y Control de la Tuberculosis. Informe 1996. La Paz, Bolivia: Secretaría Nacional de Salud, 1997.
9. World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multi-drug resistant tuberculosis (MDR-TB). WHO/CDS/TB/2000.279. Geneva, Switzerland: WHO, 2000.
10. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
11. Becerra M C, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multi-drug resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114.
12. Iseman M D. Treatment of multidrug-resistant tuberculosis. N Eng J Med 1993; 329: 784-791.
13. World Health Organization/International Union Against Tuberculosis and Lung Disease. The WHO/IUATLD Global Project On Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report No. 2. Prevalence and trends. WHO/CDS/TB/2000.278. Geneva, Switzerland: WHO, 2000.
14. Farmer P, Furin J, Bayona J, et al. Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis 1999; 3: 643-645.
15. Espinal M A, Dye C, Raviglione M, Kochi A. Rational 'DOTS Plus' for the control of MDR-TB. Int J Tuberc Lung Dis 1999; 3: 561-563.
16. Iseman M D. Tailoring a time bomb. Inadvertent genetic engineering. Am Rev Respir Dis 1985; 132: 735-736.
17. Crofton J, Chaulet P, Maher D. Guidelines for the treatment of drug-resistant tuberculosis. WHO/TB/96.210, 1997. Geneva, Switzerland: WHO, 1997.
18. The PIH guide to the management of multidrug-resistant tuberculosis. Boston, MA: Partners in Health, Program in Infectious Disease and Social Change; Department of Social Medicine, Harvard Medical School; and Division of Social Medicine and Health Inequalities, Brigham and Women's Hospital, 2003.
19. Ollé-Goig J E, Cullity J E, Vargas R. A survey of prescribing patterns for tuberculosis treatment amongst doctors in a Bolivian city. Int J Tuberc Lung Dis 1999; 3: 74-78.
20. Ollé Goig J E, Sandy R. El pronóstico de los enfermos con tuberculosis pulmonar mono y polirresistente en Santa Cruz, Bolivia. Arch Bronconeumol 2003; 39: 382-386.
21. Tahaoglu K, Törun T, Sevim T, et al. The treatment of multidrug resistant tuberculosis in Turkey. N Eng J Med 2001; 345: 170-174.
22. Park S K, Lee W C, Lee D H, Mitnick C D, Han L, Seung K J. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8: 361-368.
23. Telzak E E, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
24. Espinal M A, Kim S J, Suárez P G, et al. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
25. Harrow E M, Rangel J M, Arriega M, et al. Epidemiology and clinical consequences of drug-resistant tuberculosis in a Guatemalan Hospital. Chest 1998; 113: 1452-1458.
26. Park S K, Kim C T, Song S D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2: 877-884.
27. Kim H J, Hong Y P, Kim S J, Lew W J, Lee E G. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001; 5: 1129-1136.
28. Van Deun A, Salim M A, Das A P, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.
29. Ollé-Goig J E. Control of multidrug-resistant tuberculosis: DOTS-plus strategy will be hard to implement. [Comment] BMJ 1999; 318: 736.
30. Kim J Y, Mukherjee J S, Rich M L, Mate K, Bayona J, Becerra M C. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis 2003; 83: 59-65.
31. Ollé-Goig J E. Drugs for MDR-TB in Uganda. [Correspondence] Int J Tuberc Lung Dis 2004; 8: 271.